MARKET WIRETradingView • 14h ago
Aspire-Lakewood Holdings, Inc. Estimates – NASDAQ:ASBPTradingView report covering Aspire-Lakewood Holdings Inc. (ASBP) market action, institutional positioning, and fundamental catalysts.
Why ASBP Stock dropped -4.36% Today — RQD Quant Desk Flash
$8.11 -4.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.03
Aspire-Lakewood Holdings Inc. (ASBP) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $11.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ASBP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ASBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Aspire-Lakewood Holdings Inc. (NASDAQ: ASBP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $8.11 (-4.36% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASBP ranks #486 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ASBP compare to CALC and BIVI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASBP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of -1.9%, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and BIVI (BioVie Inc. (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $12.0M). Among the 5-stock peer group, ASBP leads on earnings multiple (N/A) while ASBP leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ASBP?
▼
Per ASBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847345), Aspire-Lakewood Holdings Inc. generated $6.2K in revenue, -$24.5M in net income, and -$4.9M in free cash flow against $1.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.03 (-0.97%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ASBP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY ASBP SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (31% of score)
FRED Regime × Technicals: 51% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$7.78+8.1% Next Q
34
Q2 (-2Q)Grade E$8.41-3% Next Q
37
Q3 (-1Q)Grade E$8.16-0.6% Next Q
39
CurrentGrade D-$8.11-7% Hist 90D α
42
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ASBP Turnaround Squeeze
While ASBP currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.56) and Max Pain ($8.52) forces dealer call-delta covering toward $16.67.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ASBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ASBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ASBP Stock dropped -4.36% Today — RQD Quant Desk Flash
Aspire-Lakewood Holdings Inc. (ASBP) dropped -4.36% to $8.11, trading at 51% of its 52-week range ($0.11 – $15.88). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 51% of its 52-week range ($0.11 – $15.88) with RSI-14 at 50 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.11 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 0% gross margin and $0 annual free cash flow.
Live ASBP Headlines & Catalysts
MARKET WIREInvesting.com UK • 17h ago
Form 8K Aspire-lakewood Holdings, Inc For: 20 October By Investing.comInvesting.com UK report covering Aspire-Lakewood Holdings Inc. (ASBP) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 54d ago
Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase ProgramBrings total authorized repurchase to $10 millionReflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunityIncreased authorization supp
MARKET WIREYahoo Finance • 55d ago
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.ESTERO, FL / ACCESS Newswire / September 8, 2026 / (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "" to "Aspire-Lakewood Holdings, Inc." The name change is effectiv
MARKET WIREYahoo Finance • 84d ago
EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS DealAspire Biopharma Holdings Inc. said Monday it completed its $30 million acquisition of Dura Driver Control Systems, expanding the biopharmaceutical company into the automotive and mobility-control market. The deal, first
MARKET WIREYahoo Finance • 115d ago
OTC Markets Life Sciences Investor Forum: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR’s David Bautz, PhDNASDAQ: ASBP Host: Hello and welcome to the Life Sciences Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research , we are very pleased you have joined us. The next presentation is from Aspire
MARKET WIREYahoo Finance • 138d ago
Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25thESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.’s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by Virtua
CATALYSTYahoo Finance • 143d ago
Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 RevenueAdds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Acquisition significantly accelerates Aspire's revenue, earnings growth and cash flow prof
MARKET WIREYahoo Finance • 143d ago
ASBP Stock Heads For Best Week In Over 2 Months – Why This Drug Delivery Tech Firm Is Buying An Auto Supplier?The company announced the acquisition of Dura Driver Control Systems for $30 million in cash.
MARKET WIREYahoo Finance • 173d ago
Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase ProgramAspire Biopharma Holdings (NASDAQ:ASBP) is one of the worst performing NASDAQ stocks so far in 2026. On April 27, Aspire Biopharma authorized a $5 million share repurchase program using existing cash. The board initiated
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ASBP)
- ✓Walkthrough of ASBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ASBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3761.90%🛡️ HOLDING TREND SUPPORT
2026-11-02O $8.88H $8.88L $8.11C $8.11VOL 31.1K
RES: $9.12SUP: $7.74SMA50: $8.56SMA200: $4.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ASBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ASBP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ASBP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ASBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ASBP)
Health Care Rank #486 of 1016
⚔️ CALC vs ASBP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ASBP vs. CALC, BIVI, BOLT, GTBP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aspire-Lakewood Holdings Inc. (ASBP) ranks #486 by composite RQD confidence (42/100, grade D-) and #881 by equity capitalization ($11.9M). Within this direct 5-issuer industry benchmark cohort, ASBP leads on earnings valuation at N/A trailing P/E, while ASBP leads on capital efficiency and profitability with -35.0% ROIC and -1.9% gross margin. ASBP currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ASBP
ACTIVE
Aspire-Lakewood Holdings Inc. | D- | 42/100 | — | -1.9% | -35.0% | -4.36% | $11.9M | Benchmark Subject |
| CALC CalciMedica Inc. | D- | 41/100 | — | — | -35.0% | -16.57% | $11.9M | /calc-vs-asbp → |
| BIVI BioVie Inc. (Class A) | E | 32/100 | — | — | -35.0% | +3.62% | $12.0M | /bivi-vs-asbp → |
| BOLT Bolt Biotherapeutics Inc. | D- | 38/100 | — | — | -35.0% | +3.62% | $12.3M | /bolt-vs-asbp → |
| GTBP GT Biopharma Inc. | D- | 36/100 | — | — | -35.0% | -5.00% | $11.5M | /gtbp-vs-asbp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001847345In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aspire-Lakewood Holdings Inc. (ASBP) reported GAAP revenue of $6.2K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$24.5M, operating cash flow of -$4.9M, and free cash flow of -$4.9M (-1756.6% YoY). On the balance sheet, ASBP closed FY2025 with $1.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.2K | -$24.5M | -$4.9M | -$4.9M | $1.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$1.3M | -$265.2K | -$265.2K | $148.0K | — |
| FY2023 (FY) | 2023-12-31 | $0 | $4.5M | -$653.1K | -$653.1K | — | — |
3. ASBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ASBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Aspire-Lakewood Holdings Inc. (NASDAQ: ASBP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $8.11 (-4.36% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASBP ranks #486 in composite RQD confidence.
How does ASBP compare to CALC and BIVI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASBP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of -1.9%, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and BIVI (BioVie Inc. (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $12.0M). Among the 5-stock peer group, ASBP leads on earnings multiple (N/A) while ASBP leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ASBP?
Per ASBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847345), Aspire-Lakewood Holdings Inc. generated $6.2K in revenue, -$24.5M in net income, and -$4.9M in free cash flow against $1.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ASBP trading relative to its 50-day, 200-day, and 52-week technical levels?
ASBP last traded at $8.11 (-4.36% on volume of 20,296 shares), positioning the stock -5.26% below its 50-day simple moving average ($8.56) and +67.22% above its 200-day simple moving average ($4.85). Across its 52-week range of $0.11 to $15.88, ASBP sits at the 50.7% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.10 to $9.12).
ASBP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ASBP stock moving today?
Why ASBP Stock dropped -4.36% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ASBP — Aspire-Lakewood Holdings Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:25Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ASBP scores 42 out of 100, grade D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support the equity valuation. Any upside case must rest on a future turn in operations that the source data does not show.
- Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. Holder-level data is not available in source data, so the drivers of this score cannot be independently traced. Investors should treat this as a modest, unverified signal.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. This is the weakest pillar and suggests insider activity provides little support for the thesis.
- Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity. The stock's market sensitivity is moderate, but this does not offset the company-specific weaknesses in the other pillars.
- Forensic Balance Sheet: 8 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The weak Piotroski reading indicates poor financial health signals, which heightens downside risk.
Taken together, the rating indicates that the valuation tradeoff is unfavorable: the stock trades at a $11.9M market capitalization against negative operating economics, leaving limited fundamental support and meaningful balance-sheet and flow risk for a prospective investor evaluating the stock today.
Business
Aspire-Lakewood Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. Revenue reported in the SEC financials is $0.0M for each period shown, so the source data does not identify a revenue-generating product or customer base. Not available in source data for product lines, customers, or revenue model.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-19.4M | $-24.5M | N/A | $-4.9M | $1.0M | N/A |
| FY 2024 | $0.0M | $-1.2M | $-1.3M | N/A | $-0.3M | N/A | N/A |
| FY 2023 | $0.0M | $0.0M | $4.5M | N/A | $-0.7M | N/A | N/A |
Per the market data, operating margin and net margin are each -60%, gross margin is -1.9%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Per the Roarable RQD rating, Debt/Equity is 0.5, but the source financials list debt as N/A for every period, so the leverage figure cannot be reconciled to reported debt in the filings.
Recent Catalysts & News Wire Analysis
Per the recent news feed, two items are listed for ASBP, both marked YELLOW and categorized as MARKET WIRE:
- A TradingView item titled "Aspire-Lakewood Holdings, Inc. Estimates – NASDAQ:ASBP," described as covering market action, institutional positioning, and fundamental catalysts. The summary contains no specific figures.
- An Investing.com UK item titled "Form 8K Aspire-lakewood Holdings, Inc For: 20 October," indicating a Form 8-K filing. The contents of that filing are not available in source data.
Risk watch items: the price is down 4.5% on the day per the market data, and the 52-week range of $0.11 - $15.88 indicates extreme price volatility. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and no proprietary signals are present.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, there are no upstream or downstream links and no proprietary signals. Not available in source data for upstream dependencies, downstream customers, or sector correlations. Investors should watch for whether the 8-K filing referenced in the news feed discloses any partnership, supplier, or financing developments that would create second-order effects; that content is not available in source data.
Open Questions
- What revenue, if any, does ASBP generate, given reported revenue of $0.0M across all periods shown?
- What is the nature of the Form 8-K filed on 20 October, and does it disclose financing, restructuring, or a material event?
- What debt balance supports the reported Debt/Equity of 0.5, given that debt is listed as N/A in every period?
- What drove the swing from net income of $4.5M in FY 2023 to net losses of $-1.3M in FY 2024 and $-24.5M in FY 2025?
- What is the source of the 52-week range low of $0.11 and high of $15.88, and what corporate events accompanied that volatility?
ASBP Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Aspire-Lakewood Holdings Inc. (ASBP) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 14h ago
Aspire-Lakewood Holdings, Inc. Estimates – NASDAQ:ASBP TradingView report covering Aspire-Lakewood Holdings Inc. (ASBP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 17h ago
Form 8K Aspire-lakewood Holdings, Inc For: 20 October By Investing.com Investing.com UK report covering Aspire-Lakewood Holdings Inc. (ASBP) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 54d ago
Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program Brings total authorized repurchase to $10 millionReflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunityIncreased authorization supp
🟡 MARKET WIRE Yahoo Finance • 55d ago
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc. ESTERO, FL / ACCESS Newswire / September 8, 2026 / (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "" to "Aspire-Lakewood Holdings, Inc." The name change is effectiv
🟡 MARKET WIRE Yahoo Finance • 84d ago
EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal Aspire Biopharma Holdings Inc. said Monday it completed its $30 million acquisition of Dura Driver Control Systems, expanding the biopharmaceutical company into the automotive and mobility-control market. The deal, first
🟡 MARKET WIRE Yahoo Finance • 115d ago
OTC Markets Life Sciences Investor Forum: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR’s David Bautz, PhD NASDAQ: ASBP Host: Hello and welcome to the Life Sciences Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research , we are very pleased you have joined us. The next presentation is from Aspire
🟡 MARKET WIRE Yahoo Finance • 138d ago
Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th ESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.’s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by Virtua
🟢 CATALYST Yahoo Finance • 143d ago
Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Acquisition significantly accelerates Aspire's revenue, earnings growth and cash flow prof
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ASBP Bull vs. Bear Conversation Board — What's Your Call at $8.11?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ASBP 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $7.46 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ASBP (D- • RQD 42/100) a Buy at $8.48?
Welcome to the ASBP (Aspire-Lakewood Holdings Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $6.78 (-20.0%)
Spot @ $8.48 Pump the brakes on ASBP — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ASBP, but look at what you are paying: current EV/EBITDA multiples with -1.9% gross margins. Unless Aspire-Lakewood Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $10.43 (+23.0%)
Spot @ $8.48 ASBP cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ASBP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.48 (52-wk range $0.11 - $15.88), any beat on forward guidance forces shorts and underweight funds to chase.